Skip to main content
. 2021 Nov 30;4(6):1835–1848. doi: 10.1021/acsptsci.1c00224

Table 3. Comparison of Ligands With Agonist Potency at Human and Mouse GPR35.

  human GPR35a, pEC50 mouse GPR35, pEC50 ratio (log) (H/M)
lodoxamide 8.38 ± 0.02 5.72 ± 0.03 2.66 ± 0.05
bufrolin 7.83 ± 0.02 6.81 ± 0.04 1.02 ± 0.06
zaprinast 5.59 ± 0.01 6.18 ± 0.01 –0.59 ± 0.0